5月12日电，美股减肥药概念股盘前加速下挫，礼来、诺和诺德跌幅扩大至逾5%。白宫官员称预计糖尿病及减肥药物将成为药品价格降低的关注重点。

Group 1 - The core viewpoint of the article indicates that U.S. stocks related to weight loss drugs are experiencing significant declines, with companies like Eli Lilly and Novo Nordisk seeing their stock prices drop by over 5% [1] - White House officials have stated that diabetes and weight loss medications are expected to be a focal point for reducing drug prices [1]